Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: Possible implications for targeted therapy

Oncology Reports

Volumn 19, Issue 2, 2008, Pages 435-440

  Shang, Jinbiao ^a,b   Shui, Yongjie ^c   Sheng, Liming ^c   Wang, Kejing ^b   Hu, Qiongge ^a   Wei, Qichun ^a,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Clinical; Epidermal growth factor receptor; Human epidermal growth factor receptor 2; Metastasis; Mucoepidermoid carcinoma; Overexpression of receptors

Indexed keywords

ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB;

ADULT; ARTICLE; CANCER SURGERY; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; PAROTID GLAND CARCINOMA; PAROTID MUCOEPIDERMOID CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCINTISCANNING; SCORING SYSTEM;

EID: 38749108776     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.2.435     Document Type: Article

References (33)

1. Pinkston JA and Cole P: Incidence rates of salivary gland tumours: results from a population based study. Otolaryngol Head Neck Surg 120: 834-840, 1999.
2. Speight PM and Barrett AW: Salivary gland tumours. Oral Dis 8: 229-240, 2002.
3. Ito FA, Ito K, Vargas PA, de Almeida OP and Lopes MA: Salivary gland tumours in a Brazilian population: a retrospective study of 496 cases. Int J Oral Maxillofac Surg 34: 533-536, 2005.
4. Li LJ, Li Y, Wen YM, Liu H and Zhao HW: Clinical analysis of salivary gland tumour cases in West China in past 50 years. Oral Oncol (In press).
5. Emerick KS, Fabian RL and Deschler DG: Clinical presentation, management, and outcome of high-grade mucoepidermoid carcinoma of the parotid gland. Otolaryngol Head Neck Surg 136: 783-787, 2007.
6. Spiro RH: Management of malignant tumours of the salivary glands. Oncology 12: 671-680, 1998.
7. Bell RB, Dierks EJ, Homer L and Potter BE: Management and outcome of patients with malignant salivary gland tumours. J Oral Maxillofac Surg 63: 917-928, 2005.
8. Hicks MJ, el-Naggar AK, Flaitz CM, Luna MA and Batsakis JG: Histocytologic grading of mucoepidermoid carcinoma of major salivary glands in prognosis and survival: a clinico-pathologic and flow cytometric investigation. Head Neck 17: 89-95, 1995.
9. Guzzo M, Andreola S, Sirizzotti G and Cantu G: Mucoepidermoid carcinoma of the salivary glands: clinicopathologic review of 108 patients treated at the National Cancer Institute of Milan. Ann Surg Oncol 9: 688-695, 2002.
10. Spiro RH, Huvos AG, Berk R and Strong EW: Mucoepidermoid carcinoma of salivary gland origin: a clinicopathologic study of 367 cases. Am J Surg 136: 461-468, 1978.
11. Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T and Tennvall J: Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 66: 107-117, 2003.
12. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR and Tortora G: Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063, 2000.
13. Hightower M: Erlotinib (OSI-774, Tarceva), a selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 4: 336-338, 2003.
14. Goldberg RM: Cetuximab. Nat Rev Drug Discov: S10-S11, 2005.
15. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK and Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006.
16. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA and Eastern Cooperative Oncology Group: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646-8654, 2005.
17. Barnes DM and Miles DW: Response of metastatic breast cancer to trastuzumab? Lancet 355: 160-161, 2000.
18. Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R and Posner M: Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 39: 724-727, 2003.
19. Locati LD, Rinaldi G, Bossi P, Dagrada GP, Quattrone P, Cantu G and Licitra L: Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncol 41: 97-98, 2005.
20. Yamada K, Iwai K, Okada Y and Mori M: Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours. Virchows Arch A Pathol Anat Histopathol 415: 523-531, 1989.
21. Gibbons MD, Manne U, Carroll WR, Peters GE, Weiss HL and Grizzle WE: Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 111: 1373-1378, 2001.
22. Glisson B, Colevas AD, Haddad R, Krane J, el-Naggar A, Kies M, Costello R, Summey C, Arquette M, Langer C, Amrein PC and Posner M: HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 10: 944-946, 2004.
23. Weed DT, Gomez-Fernandez C, Pacheco J, Ruiz J, Hamilton-Nelson K, Arnold DJ, Civantos FJ, Zhang J, Yasin M, Goodwin WJ and Carraway KL: MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma. Head Neck 26: 353-364, 2004.
24. Cho KJ, Kim JY, Lee SS and Oh KK: Mucoepidermoid carcinoma of the salivary gland-a clinicopathologic and immunohistochemical study for c-erbB-2 oncoprotein. J Korean Med Sci 12: 499-504, 1997.
25. Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG and el-Naggar AK: Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54: 5675-5682, 1994.
26. Shrestha P, Huang JW, Tsuji T, Shinozaki F, Maeda K, Sasaki K, Ueno K, Yamada K and Mori M: Rare expression of the c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. J Oral Pathol Med 21: 477-480, 1992.
27. Sugano S, Mukai K, Tsuda H, Hirohashi S, Furuya S, Shimosato Y, Ebihara S and Takeyama I: Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 102: 923-927, 1992.
28. Kernohan NM, Blessing K, King G, Corbett IP and Miller ID: Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. J Pathol 163: 77-80, 1991.
29. Wei Q, Chen L, Sheng L, Nordgen H, Wester K, Carlsson J: EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 31: 493-499, 2007.
30. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Rüschoff J, Tomasic G and van de Vijver M: Current perspectives on HER2 testing: a review of National Testing Guidelines. Mod Pathol 16: 173-182, 2003.
31. Mrhalova M, Plzak J, Betka J and Kodet R: Epidermal growth factor receptor-its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. Neoplasma 52: 338-343, 2005.
32. Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385, 2006.
33. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD and Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672, 2005.